SITAGLIPTIN TARTRATE HEMIHYDRATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	2C16H15F6N5O.2C4H6O6.H2O
Molecular Weight	1132.8162
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of SITAGLIPTIN TARTRATE HEMIHYDRATE

Structure Search

SMILES

O.O[C@H]([C@@H](O)C(O)=O)C(O)=O.O[C@H]([C@@H](O)C(O)=O)C(O)=O.N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC3=C(F)C=C(F)C(F)=C3.N[C@@H](CC(=O)N4CCN5C(C4)=NN=C5C(F)(F)F)CC6=C(F)C=C(F)C(F)=C6

InChI

InChIKey=JEMGLDGZRMYQLM-RFGXFKENSA-N

InChI=1S/2C16H15F6N5O.2C4H6O6.H2O/c2*17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22;2*5-1(3(7)8)2(6)4(9)10;/h2*4,6,9H,1-3,5,7,23H2;2*1-2,5-6H,(H,7,8)(H,9,10);1H2/t2*9-;2*1-,2-;/m1111./s1

HIDE SMILES / InChI

Molecular Formula	C16H15F6N5O
Molecular Weight	407.3136
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	( - )

Molecular Formula	C4H6O6
Molecular Weight	150.0868
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	( + )

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021995s034lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23745054 https://www.ncbi.nlm.nih.gov/pubmed/17580730

Sitagliptin (MK-0431), chemically (2R)-4-Oxo-4-[3- (trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]-1-(2,4,5-trifl uorophenyl)butan-2-amine has a very high selectivity towards DPP-4, with an IC(50) of 18 nM. There is no affinity towards other DDP enzymes (DPP- 8 and DPP-9). It has been approved for the treatment of type 2 diabetes in the USA and Europe and is registered by the name Januvia (Merck Pharmaceuticals, Whitehouse Station, NJ, USA). In healthy volunteers and in patients with type 2 diabetes of different ethnic background, the tolerability of different doses given once or twice daily is good. The drug works to competitively inhibit a protein/enzyme, dipeptidyl peptidase 4 (DPP-4), that results in an increased amount of active incretins (GLP-1 and GIP), reduced amount of release of glucagon (diminishes its release) and increased release of insulin. Sitagliptin is an incretin enhancer and the first marketed medication belonging to the gliptin class. In fact, no published literature exists regarding incidence or severity of hypoglycemia when sitagliptin is used off-label in combined with insulin therapy. However, is recommended to use methods to avoid hypoglycemia when using this off-label combination. Approximately 79% of sitagliptin is excreted unchanged in the urine with metabolism being a minor pathway of elimination. Elimination of sitagliptin occurs primarily via renal excretion and involves active tubular secretion. Sitagliptin is a substrate for human organic anion transporter-3 (hOAT-3), which may be involved in the renal elimination of sitagliptin

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dipeptidyl peptidase IV 37 Target ID: CHEMBL284 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17580730	Inhibitor 8297		18.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Type 2 diabetes mellitus 259 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021995s034lbl.pdf	Palliative		Approved 8429	JANUVIA Approved Use JANUVIA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. (1.1) Important Limitations of Use: •JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. (1.2) •JANUVIA has not been studied in patients with a history of pancreatitis. (1.2, 5.1) 1.1 Monotherapy and Combination Therapy JANUVIA® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. [See Clinical Studies (14). Launch Date 2006

C_max

Value	Dose	Co-administered	Analyte	Population
950 nM DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022044s046lbl.pdf	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		SITAGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
8.52 μM × h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022044s046lbl.pdf	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		SITAGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
12.4 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022044s046lbl.pdf	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		SITAGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
62% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022044s046lbl.pdf	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		SITAGLIPTIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
200 mg single, oral Highest studied dose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/30346099	unhealthy, 14.8 years n = 8 Health Status: unhealthy Condition: type 2 diabetes mellitus Age Group: 14.8 years Sex: M+F Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/30346099	Other AEs: Vomiting... Other AEs: Vomiting (12.5%) Sources: https://pubmed.ncbi.nlm.nih.gov/30346099
800 mg single, oral Studied dose Dose: 800 mg Route: oral Route: single Dose: 800 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021995lbl.pdf https://pubmed.ncbi.nlm.nih.gov/19602719	healthy, 18-45 years n = 77 Health Status: healthy Age Group: 18-45 years Sex: M+F Population Size: 77 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021995lbl.pdf https://pubmed.ncbi.nlm.nih.gov/19602719	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021995lbl.pdf https://pubmed.ncbi.nlm.nih.gov/19602719
1700 mg single, oral Overdose Dose: 1700 mg Route: oral Route: single Dose: 1700 mg Sources: https://pubmed.ncbi.nlm.nih.gov/22277726/	unknown, 86 years Health Status: unknown Age Group: 86 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/22277726/	Sources: https://pubmed.ncbi.nlm.nih.gov/22277726/

AEs

AE	Significance	Dose	Population
Vomiting	12.5%	200 mg single, oral Highest studied dose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/30346099	unhealthy, 14.8 years n = 8 Health Status: unhealthy Condition: type 2 diabetes mellitus Age Group: 14.8 years Sex: M+F Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/30346099

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inducer 781 inhibitor 1587	inhibitor 1767	inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OCT transporters 14 CYP 111 P-gp 1461 OAT3 642 CYP1A2 1524 CYP2B6 810 CYP2C8 911 CYP2C19 1478	CYP2C8 693 OAT3 339 P-gp 1537 OAT1 326 PEPT1 49 OCT2 355 OAT4 78

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021995s000_ClinPharmR.pdf Page: 15.0	no [IC50 >100 uM]
CYP2B6 1001	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021995s000_ClinPharmR.pdf Page: 15.0	no [IC50 >100 uM]
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021995s000_ClinPharmR.pdf Page: 15.0	no [IC50 >100 uM]
CYP2C8 965	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021995s000_ClinPharmR.pdf Page: 15.0	no [IC50 >100 uM]
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021995s000_ClinPharmR.pdf Page: 15.0	no [IC50 >100 uM]
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021995s000_ClinPharmR.pdf Page: 15.0	no [IC50 >100 uM]
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021995s000_ClinPharmR.pdf Page: 15, 30	no [IC50 >100 uM]	no (co-administration study) Comment: results indicated that sitagliptin was not a time-dependent inhibitor of CYP3A4; sitagliptin did not meaningfully alter the pharmacokinetics of simvastatin. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021995s000_ClinPharmR.pdf Page: 15, 30
CYP 147	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022044s000_PharmR.pdf Page: 6.0	no
CYP3A4 1925	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021995s000_ClinPharmR.pdf Page: 15.0	no
OAT3 644	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022044s000_PharmR.pdf Page: 6.0	no
OCT transporters 14	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022044s000_ClinPharmR.pdf Page: 9.0	no
P-gp 1650	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021995s000_ClinPharmR.pdf Page: 15.0	no	no (co-administration study) Comment: sitagliptin had no inhibitory effect on the P-gp mediated transport of digoxin, verapmil, ritonavir, adn vinblastine Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021995s000_ClinPharmR.pdf Page: 15.0

Drug as victim

Target	Modality	Activity	Clinical evidence
OAT4 78	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021995s000_ClinPharmR.pdf Page: 15.0	inconclusive
OAT1 326	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021995s000_ClinPharmR.pdf Page: 15.0	no
OCT2 355	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021995s000_ClinPharmR.pdf Page: 15.0	no
PEPT1 49	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021995s000_ClinPharmR.pdf Page: 15.0	no
CYP2C8 693	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021995s000_ClinPharmR.pdf Page: 4, 42	yes
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021995s000_ClinPharmR.pdf Page: 4, 42	yes
OAT3 339	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021995s000_ClinPharmR.pdf Page: 4, 15	yes
P-gp 1537	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021995s000_ClinPharmR.pdf Page: 4, 15	yes	yes (co-administration study) Comment: cyclosporin A significantly inhibited P-gp transport of sitagliptin Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021995s000_ClinPharmR.pdf Page: 4, 15

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021995s000_PharmR.pdf Page: 22, 23

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:40237	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:40237
ChemicalBook	CB01449778	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB01449778
MolPort	MolPort-003-666-756	https://www.molport.com/shop/molecule-link/MolPort-003-666-756
ZINC	ZINC000001489478	http://zinc15.docking.org/substances/ZINC000001489478
eMolecules	6755163	https://www.emolecules.com/cgi-bin/more?vid=6755163

PubMed

Title	Date	PubMed
Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.	2007	17352677
Sitagliptin: a viewpoint by Itamar Raz.	2007	17352518
Sitagliptin: a viewpoint by Mark S. Kipnes.	2007	17352517
Sitagliptin.	2007	17352516
Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.	2007 Apr	17407649
Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.	2007 Apr	17371200
beta-cell failure in diabetes and preservation by clinical treatment.	2007 Apr	17353295
Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs.	2007 Apr	17220241
Characterization of two cyclic metabolites of sitagliptin.	2007 Apr	17220240
Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans.	2007 Apr	17220239
[Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application].	2007 Apr 1	17383951
Type 2 diabetes: the end of clinical inertia.	2007 Aug	17713297
Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors.	2007 Aug	17593275
Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight.	2007 Aug	17593274
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.	2007 Aug	17485570
Sitagliptin.	2007 Feb	17342863
Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects.	2007 Feb	17244767
Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects.	2007 Feb	17244766
Finding new treatments for diabetes--how many, how fast... how good?	2007 Feb 1	17267901
[New class of oral antidiabetic drugs. Effective in combination with metformin].	2007 Jan	17619359
Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.	2007 Jan	17315049
New treatment for diabetes.	2007 Jan-Feb	17342826
New drugs: sitagliptin phosphate, telbivudine, and panitumumab.	2007 Jan-Feb	17338483
The physiology of incretin hormones and the basis for DPP-4 inhibitors.	2007 Jan-Feb	17272793
Management of comorbid diabetes and cancer.	2007 Jul	17844893
A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies.	2007 Jul	17559747
[New concepts in the treatment of type 2 diabetes].	2007 Jul	17541529
Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor.	2007 Jul	17468348
Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.	2007 Jun	17559733
Does addition of sitagliptin to metformin monotherapy improve glycemic control in patients with type 2 diabetes mellitus?	2007 Jun	17457306
Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.	2007 Jun	17337494
Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: close analogs of JANUVIA (sitagliptin phosphate).	2007 Jun 15	17434732
Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin.	2007 Jun 15	17433672
Diabetes drug update: how 4 new options stack up.	2007 Mar	17343811
Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.	2007 Mar	17300594
Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug.	2007 Mar	17300591
Treatment of type 2 diabetes mellitus and the incretin system.	2007 May	17694940
Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin.	2007 May	17392725
Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein.	2007 May	17314201
New treatments for diabetes.	2007 May 24	17526096
New treatments for diabetes.	2007 May 24	17526095
New treatments for diabetes.	2007 May 24	17526094
New treatments for diabetes.	2007 May 24	17522409
Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.	2007 Sep	17877544
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.	2007 Sep	17593236
Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.	2007 Sep	17575559
Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.	2007 Sep	17571284
Sensitive liquid chromatography tandem mass spectrometry method for the quantification of sitagliptin, a DPP-4 inhibitor, in human plasma using liquid-liquid extraction.	2008 Feb	17939170
Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes.	2008 Feb	17933414
Dipeptidyl peptidase IV inhibitors and diabetes therapy.	2008 Jan 1	17981665

Patents

Sample Use Guides

In Vivo Use Guide

100 mg once daily. It can be taken with or without food.

Route of Administration: Oral

In Vitro Use Guide

Adipose tissue from adult-male Fischer 344 rats were cultured in endothelial progenitor cell culture medium for 14 d with (25 μmol/L) or without sitagliptin.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 18:19:04 GMT 2023` Edited by `admin` on `Sat Dec 16 18:19:04 GMT 2023`
Record UNII	79C7Y78XGP
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SITAGLIPTIN TARTRATE HEMIHYDRATE

Common Name

English

SITAGLIPTIN (+)-TARTRATE HEMIHYDRATE

Common Name

English

1,2,4-TRIAZOLO(4,3-A)PYRAZINE, 7-((3R)-3-AMINO-1-OXO-4-(2,4,5-TRIFLUOROPHENYL)BUTYL)-5,6,7,8-TETRAHYDRO-3-(TRIFLUOROMETHYL)-, (2R,3R)-2,3-DIHYDROXYBUTANEDIOATE, HYDRATE (2:2:1)

Common Name

English

Code System Code Type Description

PUBCHEM

131738936

Created by admin on Sat Dec 16 18:19:04 GMT 2023 , Edited by admin on Sat Dec 16 18:19:04 GMT 2023

PRIMARY

FDA UNII

79C7Y78XGP

Created by admin on Sat Dec 16 18:19:04 GMT 2023 , Edited by admin on Sat Dec 16 18:19:04 GMT 2023

PRIMARY

CAS

862156-93-2

Created by admin on Sat Dec 16 18:19:04 GMT 2023 , Edited by admin on Sat Dec 16 18:19:04 GMT 2023

PRIMARY

SMS_ID

100000172038

Created by admin on Sat Dec 16 18:19:04 GMT 2023 , Edited by admin on Sat Dec 16 18:19:04 GMT 2023

PRIMARY

Related Record Type Details


					QFP0P1DV7Z

SITAGLIPTIN

PARENT -> SALT/SOLVATE

Amount:

Details

SMILES

InChI

DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021995s034lbl.pdfCurator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23745054 https://www.ncbi.nlm.nih.gov/pubmed/17580730

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Cmax

AUC

T1/2

Funbound

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Tox targets

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021995s034lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23745054 https://www.ncbi.nlm.nih.gov/pubmed/17580730

C_max

T_1/2

F_unbound

Drug as perpetrator